全文获取类型
收费全文 | 469篇 |
免费 | 21篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 4篇 |
基础医学 | 37篇 |
口腔科学 | 4篇 |
临床医学 | 24篇 |
内科学 | 209篇 |
皮肤病学 | 4篇 |
神经病学 | 8篇 |
特种医学 | 9篇 |
外科学 | 51篇 |
综合类 | 5篇 |
预防医学 | 11篇 |
眼科学 | 8篇 |
药学 | 22篇 |
肿瘤学 | 92篇 |
出版年
2024年 | 1篇 |
2023年 | 1篇 |
2022年 | 16篇 |
2021年 | 14篇 |
2020年 | 8篇 |
2019年 | 4篇 |
2018年 | 18篇 |
2017年 | 11篇 |
2016年 | 7篇 |
2015年 | 8篇 |
2014年 | 9篇 |
2013年 | 14篇 |
2012年 | 30篇 |
2011年 | 27篇 |
2010年 | 14篇 |
2009年 | 23篇 |
2008年 | 25篇 |
2007年 | 38篇 |
2006年 | 42篇 |
2005年 | 20篇 |
2004年 | 15篇 |
2003年 | 15篇 |
2002年 | 9篇 |
2001年 | 6篇 |
2000年 | 13篇 |
1999年 | 8篇 |
1998年 | 6篇 |
1997年 | 1篇 |
1996年 | 8篇 |
1995年 | 6篇 |
1994年 | 4篇 |
1993年 | 2篇 |
1992年 | 14篇 |
1991年 | 6篇 |
1990年 | 9篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1987年 | 5篇 |
1986年 | 8篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 2篇 |
1960年 | 1篇 |
排序方式: 共有490条查询结果,搜索用时 15 毫秒
1.
A R Zander S Culbert S Jagannath G Spitzer M Keating N Larry K Cockerill J Hester L Horwitz L Vellekoop 《Cancer》1987,59(6):1083-1086
A high dose combination chemotherapy regimen (CBV) consisting of cyclophosphamide (1.5 gm/m2 day 1 to day 4); BCNU (300 mg/m2 day 1) and etoposide (100 mg/m2 every 12 hours for 6 doses), followed by bone marrow transplant from human leukocyte antigen (HLA) identical sibling donors, was evaluated in 29 patients in whom acute leukemia was in relapse or remission. Engraftment of donor cell type occurred in all but one of 21 patients, in whom marker differences between donor and recipient were established. Two of 11 patients transplanted during relapse of the disease, lived beyond 1 year after bone marrow transplantation. One patient died free of leukemia, 41 months after transplantation of meningitis. Two of seven patients transplanted during the second remission of the disease, are alive and free of leukemia at 42+, and 8+ months. All patients transplanted during the third or fourth remission of the disease have died from either a further relapse, or transplant related causes. The low incidence of organ toxicity with CBV allows for further dose escalation of its drug components. 相似文献
2.
K A Dinshaw S C Pande S K Shrivastava M A Gonsalves S H Advani R Gopal S S Shrikhande L J Desouza P Jagannath P B Desai 《Journal of surgical oncology》1992,49(1):39-44
A retrospective analysis of 328 cases of Hodgkin's Disease (HD) subjected to a staging laparotomy at the Tata Memorial Hospital, Bombay, India, from 1974 to 1986 was undertaken to assess its relevance to our setup. Eighty percent of the patients were from clinical stages (CS) I and II, 38% with lymphocyte predominance (LP), and 41% with mixed cellularity (MC) histologies. Staging laparotomy was positive in 60% cases overall, including 50% from CS IA and IIA, 68% from CS IB and IIB, and 53% and 67%, respectively, from LP and MC histologies. Splenic involvement was seen in 54% cases. Operative complications were encountered in 2% of cases and deaths in two cases only. In view of the high propensity for abdominal spread, only selected CS IA and IIA cases would merit a staging laparotomy within which, nearly 50% cases with a negative yield could be offered radical segmental irradiation alone for cure. The majority of our patients would, however, require combination therapy. 相似文献
3.
4.
Chandralekha Tampi Prashant Mullerpatan Rajiv Shah Palepu Jagannath Arthur Zimmermann 《Pancreatology》2006,6(3):248-253
Microcystic adenoma or serous cystadenoma is an uncommon tumor and accounts for 1-2% of the exocrine neoplasms of the pancreas. Usually unifocal, they present as single, large, well-demarcated multiloculated cystic tumors, ranging in size from 1 to 25 cm. Multifocal variants or diffuse serous cystadenomas are extremely rare. We present 2 cases of which 1 is a diffuse variant affecting the body, tail and part of the neck of the pancreas. In both the patients the tumors were detected incidentally. We highlight on the diffuse variant in view of its rarity and present a review of literature. In this case the entire body and tail of the pancreas was spongy replaced by multicystic lobules and hyalinized fibrocollagenous stroma. The cysts were lined by low cuboidal glycogen containing bland cells. Such a unique presentation wherein the entire body and tail of the pancreas is replaced with multiple cysts is a diffuse presentation of microcystic adenoma and a search through literature revealed only 7 such cases among the 15 cases with multifocal presentation reported. 相似文献
5.
6.
7.
Shaji Kumar Lawrence Baizer Natalie S. Callander Sergio A. Giralt Jens Hillengass Boris Freidlin Antje Hoering Paul G. Richardson Elena I. Schwartz Anthony Reiman Suzanne Lentzsch Philip L. McCarthy Sundar Jagannath Andrew J. Yee Richard F. Little Noopur S. Raje 《Blood cancer journal》2022,12(6)
A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the appropriate choice of treatment(s) for the next phase of the disease. Additionally, an important subset of MM patients will prove to be refractory to the majority of the available treatments, requiring selection of effective therapies from the remaining options. Immunomodulatory agents (IMiDs), proteasome inhibitors, monoclonal antibodies, and alkylating agents are the major classes of MM therapies, with several options in each class. Patients who are refractory to one agent in a class may be responsive to a related compound or to a drug from a different class. However, rules for selection of alternative treatments in these situations are somewhat empirical and later phase clinical trials to inform those choices are ongoing. To address these issues the NCI Multiple Myeloma Steering Committee formed a relapsed/refractory working group to review optimal treatment choices, timing, and sequencing and provide recommendations. Additional issues considered include the role of salvage autologous stem cell transplantation, risk stratification, targeted approaches for genetic subsets of MM, appropriate clinical trial endpoints, and promising investigational agents. This report summarizes the deliberations of the working group and suggests potential avenues of research to improve the precision, timing, and durability of treatments for Myeloma.Subject terms: Combination drug therapy, Cancer therapeutic resistance, Targeted therapies 相似文献
8.
9.
10.
Thuluvath PJ Maheshwari A Jagannath S Arepally A 《Digestive diseases and sciences》2005,50(2):407-410
Primary prophylaxis with nonselective -blockers in high-risk subjects has been shown to be effective in reducing both esophageal variceal bleeding and mortality. Recently it has been suggested that band ligation may be a better option for primary prophylaxis. We compared nonselective -blockers with band ligation in patients with large varices (F2, F3) and elevated hepatic venous wedge pressure gradient (HVWPG, 12 mm Hg). All patients were prospectively followed for variceal bleeding, mortality, and treatment-related complications. Based on previous published studies, we estimated that 90 patients in each arm would be required to show a difference in bleeding rate. The study was prematurely terminated when we realized that our estimated sample size was inadequate to show a difference based on the observed bleeding rate. At the time of termination, 31 patients (Child A, 11; B, 14; C, 6), with a mean HVWPG of 19 ± 9.1 mm Hg, were randomized to either band ligation (group A; n = 16) or -blockers (group B; n = 15). Baseline demographics of both groups were similar and the mean follow-up period was 27.4 ± 12.9 months. During the follow-up, two patients in group A and one patient in group B had bleeding. Nine patients (29%; group A, six; group B, three; P = ns) died due to non-bleeding-related causes and five (16%) patients (group A, three; group B, two) underwent liver transplantation. Treatment-related complication were minimal in both groups. Despite the selection of high-risk patients, the observed bleeding rate was much lower than anticipated. Based on our observed bleeding rates, 424 patients would be required in each arm to show a difference between band ligation and -blocker therapy. 相似文献